About
Portfolio
Team
News
Contact
中文
About
Portfolio
Team
News
Contact
中文
Home
News
News
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb
2023-9-06
与诺华“联姻”后,Chinook又携两项核心资产“炸场”ERA年会
2023-6-21
神领锐医药宣布与台湾晶实公司签署独家经销协议
2023-4-20
合凯维生命科学首次亮相,完成近千万美元的种子轮融资,进军全球女性健康市场
2023-3-08
2022 ASN肾脏周披露最新数据 | BION-1301治疗显著降低IgA肾病患者尿蛋白水平
2022-11-16
Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
2022-11-07
Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trialof ARVN002 for Progressive Myopia This marks yet another successful expansion of Arctic Vison's MAP™ technology in the field of ophthalmic therapeutics
2022-9-28
Arctic Vision Announces First-Ever Application of Triamcinolone Acetonide Injectable Suspension for Suprachoroidal Use for the Treatment of UME in Boao
2022-9-26
OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors
2022-9-12
Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies
2022-8-05
Novaremed enters into an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore
2022-7-21
Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia
2022-7-04
Arctic Vision Announces First Patient Dosed in Phase 1 Clinical Trial of ARVN001 for the Treatment of Diabetic Macular Edema (DME) in China
2022-3-03
Plexium Announces $102m Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform
2022-2-23
OncXerna is selected as Global Top 5 Precision Medicine Startups
2022-2-17
Arctic Vision Enters Strategic Partnership with MediTrust Health to Improve Accessibility and Affordability of Innovative Ophthalmic Drugs in China
2022-1-26
Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
2022-1-10
Arctic Vision Wins Leading-Edge Enterprise of the Year Award at the 36Kr WISE 2021 New Economy Summit
2021-12-14
Pivotal bioVenture Partners China Announces Formation of SanReno Therapeutics
2021-12-03
Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market
2021-11-29
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
2021-11-23
Arctic Vision Enters Strategic Collaboration with Eye Hospital, WMU
2021-11-12
Arctic Vision Enters Strategic Partnership with SPH Health Commerce to Boost Development and Delivery of Innovative Ophthalmology Therapies in China
2021-11-05
Arctic Vision announced residency at JLABS @ Shanghai to further the Development of Innovative Ophthalmic Therapy Discovery Platform
2021-11-03
Arctic Vision’s Collaboration Partner, Clearside Biomedical Inc., Has Obtained U.S. FDA Approval of XIPERE™ (ARVN001) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
2021-10-26
Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal
2021-9-17
Arctic Vision Announces 2nd Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include Australia and New Zealand
2021-9-10
Arctic Vision Obtains China IND Clearance for Phase III Study of ARVN003, the First in China for Presbyopia Treatment
2021-9-03
Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India
2021-8-15
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
2021-8-09
Engrail Therapeutics Extends Series A Financing to $64 Million
2021-8-03
Arctic Vision Received China IND Clearance for Phase III Study of ARVN002 to Reduce Paediatric Myopia Progression
2021-8-02
NeuroFront Announces Exclusive Licensing Agreement for Development and Commercialization of Neurolief’s Relivion® in Greater China and South Korea
2021-7-09
Exscientia announces investment of up to $525M
2021-4-26
Evommune完成1250万美元种子轮融资
2020-11-20
Oncologie(鼎航医药)公布最新临床研究数据
2020-9-21
Arctic Vision Announces US$32MN in Series A
2020-7-14
Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China
2018-6-07
Pivotal bioVenture Partners China Closes Inaugural $150 Million Early Stage VC Fund
2018-5-24